Yu Y, Bi Z M, Wang Y, Chen Z Q, Xu S W
*Department of Hemodialysis, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, China.
Zhonghua Yi Xue Za Zhi. 2016 Dec 13;96(46):3724-3728. doi: 10.3760/cma.j.issn.0376-2491.2016.46.007.
To investigate the factors correlated to coronary artery calcification (CAC)in maintenance hemodialysis (MHD) patients and observe the effect of sodium thiosulfate (STS) on the progression of vascular calcification and its safety. Thirty-eight subjects from Fuzhou Genernal Hospital who underwent coronary artery CT scan using Philip's spiral CT were enrolled and the calcification degree was evaluated by CAC scores from December 2013 to December 2014. The hemodialysis patients were divided into CAC group (CAC scores>10, 27 cases) and non-CAC group (CAC scores≤10, 11 cases)according to the CT scan results.The differences of age, duration of dialysis, blood pressure and other hematological indices between the two groups were analyzed to investigate the factors correlated to CAC. Next, those with CAC (CAC scores≥50) received intravenous 0.18 g/kg STS (dissolved in 100 ml saline) in 30 minutes after each dialysis for 3 months (=17, only 15 patients completed STS treatment) or received conventional treatment (=10). Baseline data between the two groups before treatment had no significant statistical difference. All examination indices were evaluated before and after the treatment course. The changes of vascular calcification imaging, CAC scores, biochemical indices and bone mineral density were compared between two groups before and after the treatment. Besides, adverse reactions were observed during the treatment of STS. This study was approved by the Ethics Committee of Fuzhou General Hospital(2013No1). Twenty-seven out of 38 patients (71.05%) had CAC, and the patients with CAC had significantly higher age, phosphate, the product of calcium and phosphate, intact parathyroid hormone (hPTH), hypersensitive C-reactive protein (hsCRP), and longer duration of dialysis (=0.017, 0.038, 0.037, 0.012, 0.002, 0.037) and lower serum albumin (=0.026) than patients without CAC.There was no significant statistical difference in the baseline characteristics. CAC score did not change significantly before and after treatment in the STS treatment group[1 045(47-12 734) vs 797(50-14 094), =0.053], but increased significantly in the conventional treatment group[221(59-3 843) vs 174(50-3 369), =0.021]. Difference of CAC score parameters before and after treatment showed statistically significant difference between the two groups[-67.5(-474-8) vs 52(-248-1 361) , =0.004]. After STS treatment, level of hsCRP and HCO decreased (=0.016 and =0.020, respectively), and level of serum calcium increased (=0.005). There was no significant statistical difference observed in iPTH, 25(OH)D, bone alkaline phosphatase (bALP), fibroblast growth factor 23 (FGF23) after STS treatment. STS treatment seems to be feasible, safe and may delay the rate of progression of vascular calcification, reduce inflammation in maintenance hemodialysis patients, but the adverse reactions needs further study.
为研究维持性血液透析(MHD)患者冠状动脉钙化(CAC)的相关因素,并观察硫代硫酸钠(STS)对血管钙化进展的影响及其安全性。选取2013年12月至2014年12月在福州总医院行飞利浦螺旋CT冠状动脉扫描的38例患者,通过CAC积分评估钙化程度。根据CT扫描结果将血液透析患者分为CAC组(CAC积分>10,27例)和非CAC组(CAC积分≤10,11例)。分析两组患者年龄、透析时间、血压及其他血液学指标的差异,以研究与CAC相关的因素。接下来,将CAC患者(CAC积分≥50)分为两组,一组在每次透析后30分钟内静脉输注0.18 g/kg STS(溶于100 ml生理盐水中),共3个月(n = 17,仅15例患者完成STS治疗),另一组接受常规治疗(n = 10)。两组治疗前基线数据无显著统计学差异。在治疗疗程前后评估所有检查指标。比较两组治疗前后血管钙化影像学、CAC积分、生化指标及骨密度的变化。此外,观察STS治疗期间的不良反应。本研究经福州总医院伦理委员会批准(2013No1)。38例患者中27例(71.05%)存在CAC,与无CAC患者相比,CAC患者年龄、血磷、钙磷乘积、全段甲状旁腺激素(iPTH)、超敏C反应蛋白(hsCRP)显著更高,透析时间更长(P = 0.017、0.038、0.037、0.012、0.002、0.037),血清白蛋白更低(P = 0.026)。基线特征无显著统计学差异。STS治疗组治疗前后CAC积分无显著变化[1 045(47 - 12 734)对797(50 - 14 094),P = 0.053],但常规治疗组显著增加[221(59 - 3 843)对174(50 - 3 369),P = 0.021]。两组治疗前后CAC积分参数差异有统计学意义[-67.5(-474 - 8)对52(-248 - 1 361),P = 0.004]。STS治疗后,hsCRP水平和HCO降低(分别为P = 0.016和P = 0.020),血清钙水平升高(P = 0.005)。STS治疗后iPTH、25(OH)D、骨碱性磷酸酶(bALP)、成纤维细胞生长因子23(FGF23)无显著统计学差异。STS治疗似乎可行、安全,可能延缓维持性血液透析患者血管钙化进展速度,减轻炎症,但不良反应有待进一步研究。